PACE AS TREATMENT OF RESCUE IN PATIENTS WITH MULTIPLE RELAPSED OR REFRACTORY MYELOMA

被引：0
|
作者：
Isola, I. [1 ]
Granell, M. [2 ]
Marti Josep, M. [3 ]
Gironella, M. [4 ]
Garcia-Guinon, A. [5 ]
Lopez-Pardo, J. [2 ]
Muntanola, A. [3 ]
Abella, E. [6 ]
Motllo, C. [7 ]
Escoda, L. [8 ]
Sierra, J. [2 ]
Blade, J. [1 ]
Rosinol, L. [1 ]
Fernandez de larrea, C. [1 ]
机构：
[1] Hosp Clin Barcelona, Serv Hematol, Unidad Amiloidosis & Mieloma, IDIBAPS, Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, Serv Hematol, Barcelona, Spain
[3] Hosp Mutua Terrassa, Serv Hematol, Terrassa, Spain
[4] Hosp Valle De Hebron, Serv Hematol, Barcelona, Spain
[5] Hosp Arnau Vilanova, Serv Hematol, Lleida, Spain
[6] Hosp del Mar, Serv Hematol, Barcelona, Spain
[7] Hosp Badalona Germans Trias & Pujol, Serv Hematol, Badalona, Spain
[8] Hosp Joan 23, Serv Hematol, Tarragona, Spain
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO-070
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [41] Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
    Parsons, Janet
    Greenspan, Nicole
    Baker, Natalie
    McKillop, Chris
    Hicks, Lisa
    Chan, Olivia
    BMC CANCER, 2019, 19 (1)
  • [42] Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma
    Zangari, Maurizio
    Guerrero, Jose
    Cavallo, Federica
    Prasad, H. Keshava
    Esseltine, Dixie
    Fink, Louis
    HAEMATOLOGICA, 2008, 93 (06) : 953 - 954
  • [43] Efficacy and Safety of VTD-PACE Regimen in Relapsed or Refractory Multiple Myeloma
    Andoh, Shohei
    Togano, Tomiteru
    Itoi, Satoru
    Mitsui, Yurika
    Hirai, Risen
    Tanimura, Akira
    Sekine, Rieko
    Hagiwara, Shotaro
    Miwa, Akiyoshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E57 - E57
  • [44] Emerging therapies for the treatment of relapsed or refractory multiple myeloma
    Dimopoulos, Meletios A.
    San-Miguel, Jesus F.
    Anderson, Kenneth C.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (01) : 1 - 15
  • [45] Current strategies for treatment of relapsed/refractory multiple myeloma
    Laubach, Jacob P.
    Voorhees, Peter M.
    Hassoun, Hani
    Jakubowiak, Andrzej
    Lonial, Sagar
    Richardson, Paul G.
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (01) : 97 - 111
  • [46] The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma
    Comeau, Jill M.
    Kelly, Katherine
    Jean, Gary W.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (02) : 55 - 66
  • [47] Current treatment landscape for relapsed and/or refractory multiple myeloma
    Dimopoulos, Meletios A.
    Richardson, Paul G.
    Moreau, Philippe
    Anderson, Kenneth C.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (01) : 42 - 54
  • [48] Current treatment landscape for relapsed and/or refractory multiple myeloma
    Meletios A. Dimopoulos
    Paul G. Richardson
    Philippe Moreau
    Kenneth C. Anderson
    Nature Reviews Clinical Oncology, 2015, 12 : 42 - 54
  • [49] Prolonged treatment with lenalidomide in relapsed and refractory multiple myeloma
    Franco C.A.
    Palomera L.
    Arredondo J.J.R.
    Sánchez J.M.
    Advances in Therapy, 2011, 28 (Suppl 8) : 14 - 19
  • [50] An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma
    Avigan, Zachary M.
    Rattu, Mohammad A.
    Richter, Joshua
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (03) : 221 - 228
12345